全文获取类型
收费全文 | 127篇 |
免费 | 10篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 14篇 |
临床医学 | 9篇 |
内科学 | 33篇 |
神经病学 | 12篇 |
特种医学 | 14篇 |
外科学 | 8篇 |
综合类 | 6篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 12篇 |
中国医学 | 1篇 |
肿瘤学 | 25篇 |
出版年
2022年 | 2篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 3篇 |
2016年 | 1篇 |
2015年 | 5篇 |
2014年 | 2篇 |
2013年 | 5篇 |
2012年 | 7篇 |
2011年 | 13篇 |
2010年 | 4篇 |
2009年 | 2篇 |
2008年 | 4篇 |
2007年 | 14篇 |
2006年 | 10篇 |
2005年 | 9篇 |
2004年 | 11篇 |
2003年 | 11篇 |
2002年 | 7篇 |
2001年 | 2篇 |
2000年 | 3篇 |
1999年 | 5篇 |
1998年 | 1篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1983年 | 1篇 |
1971年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有137条查询结果,搜索用时 18 毫秒
1.
Alicia M. Blessing MD PhD Janice M. Santiago-O'Farrill MD PhD Weiqun Mao BS MD Lan Pang BS MD Jing Ning MD PhD Daewoo Pak MD PhD Lakshmi Reddy Bollu MD PhD Philip Rask BS MD LaKesla Iles BS MD Hailing Yang PhD MD Samantha Tran BS MD Ezzeddine Elmir BS MD Geoffrey Bartholomeusz MD PhD Robert Langley MD PhD Zhen Lu MD Robert C. Bast Jr MD 《Cancer》2020,126(15):3579-3592
2.
3.
4.
Advances in hepatitis C: What is coming in the next 5 years? 总被引:3,自引:0,他引:3
Hepatitis C virus (HCV) is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Numerous advances have been made in the understanding of HCV replication, including detailed molecular characterization of its viral proteins and genomic RNA. The inability to grow HCV in cell culture had impeded the development of antiviral agents against this virus. To overcome this obstacle, a number of unique tools have been prepared, such as molecular clones that are infectious in the chimpanzee animal model of infection, and the development of a subgenomic replicon system in Huh7 cells. In addition, the major non-structural proteins have been crystallized, thus enabling rational drug design directed to these targets. Current developments in antiviral agents are reviewed in the context of these potential new viral targets for the future treatment of HCV in chronically infected individuals. 相似文献
5.
Revill PA Littlejohn M Ayres A Yuen L Colledge D Bartholomeusz A Sasaduesz J Lewin SR Dore GJ Matthews GV Thio CL Locarnini SA 《AIDS (London, England)》2007,21(13):1701-1710
OBJECTIVES: Although HAART has resulted in improved health outcomes for most HIV-infected individuals, liver failure has emerged as a major cause of morbidity and mortality in people co-infected with hepatitis B virus (HBV). In HBV mono-infected individuals, core deletion mutants are associated with more aggressive liver disease. As HIV accelerates HBV liver disease progression, we hypothesized that HIV-HBV co-infected individuals have increased frequency of core mutations including deletions. To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy. SETTING: Prospective HIV/HBV co-infected cohort study. METHODS: Genomic length HBV DNA was amplified by PCR from the serum samples of ten HIV/HBV co-infected individuals and five HBV mono-infected individuals prior to the commencement of lamivudine therapy and again after nine to 74 months of treatment. The complete genomes were sequenced and in order to further analyse some mutations, their frequency was determined in additional HIV/HBV co-infected and HBV mono-infected individuals. RESULTS: A novel -1G mutation was identified in the HBV precore and overlapping core genes that truncated the deduced precore/core proteins. The mutant genome was the dominant species in some HIV/HBV co-infected individuals and was more prevalent in HIV/HBV co-infected individuals than HBV mono-infected individuals. The mutation was also associated with high HBV DNA concentrations in HIV/HBV co-infected individuals. Additional mutations were identified in the core/precore and polymerase genes and regulatory regions. CONCLUSION: Mutations in the HBV core and precore genes may be contributing to disease pathogenesis in HIV/HBV co-infected individuals. 相似文献
6.
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management 总被引:21,自引:0,他引:21
Lok AS Zoulim F Locarnini S Bartholomeusz A Ghany MG Pawlotsky JM Liaw YF Mizokami M Kuiken C;Hepatitis B Virus Drug Resistance Working Group 《Hepatology (Baltimore, Md.)》2007,46(1):254-265
Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy. 相似文献
7.
8.
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine 总被引:50,自引:0,他引:50 下载免费PDF全文
9.
Wannan Cassandra M. J. Bartholomeusz Cali F. Pantelis Christos Di Biase Maria A. Syeda Warda T. Chakravarty M. Mallar Bousman Chad A. Everall Ian P. McGorry Patrick D. Zalesky Andrew Cropley Vanessa L. 《European archives of psychiatry and clinical neuroscience》2022,272(6):971-983
European Archives of Psychiatry and Clinical Neuroscience - Episodic memory ability relies on hippocampal-prefrontal connectivity. However, few studies have examined relationships between memory... 相似文献
10.
Brown C Howes B Jamieson GG Bartholomeusz D Zingg U Sullivan TR Thompson SK 《World journal of surgery》2012,36(5):1089-1095